Effect of Antenatal Corticosteroids on Respiratory Morbidity in Singletons After Late-Preterm Birth by Gyamfi-Bannerman, Cynthia et al.
Effect of Antenatal Corticosteroids on Respiratory Morbidity in
Singletons After Late-Preterm Birth
Cynthia Gyamfi-Bannerman, MD, Sharon Gilbert, MS, MBA, Mark B. Landon, MD, Catherine
Y. Spong, MD, Dwight J. Rouse, MD, Michael W. Varner, MD, Paul J. Meis, MD, Ronald J.
Wapner, MD, Yoram Sorokin, MD, Marshall Carpenter, MD, Alan M. Peaceman, MD, Mary J.
O'Sullivan, MD, Baha M. Sibai, MD, John M. Thorp, MD, Susan M. Ramin, MD, Brian M.
Mercer, MD, and for the Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU)*
Departments of Obstetrics and Gynecology at Columbia University, New York, NY; The Ohio
State University, Columbus, OH; University of Alabama at Birmingham, Birmingham, AL;
University of Utah, Salt Lake City, UT; Wake Forest University Health Sciences, Winston-Salem,
NC; Thomas Jefferson University, Philadelphia, PA; Wayne State University, Detroit, MI; Brown
University, Providence, RI; Northwestern University, Chicago, IL; University of Miami, Miami, FL;
University of Tennessee, Memphis, TN; University of North Carolina at Chapel Hill, Chapel Hill,
NC; University of Texas Health Science Center at Houston, Houston, TX; Case Western Reserve
University-MetroHealth Medical, Cleveland, OH and The George Washington University
Biostatistics Center, Washington, DC, and the Eunice Kennedy Shriver National Institute of Child
Health and Human Development, Bethesda, MD
Abstract
Objective—To evaluate whether neonates born to women who had previously received antenatal
corticosteroids and then delivered a late-preterm birth neonate had less respiratory morbidity
compared with those unexposed to antenatal corticosteroids.
Methods—This is a secondary analysis from a multicenter observational study regarding mode
of delivery after prior cesarean delivery. We compared women who received one course of
antenatal corticosteroids with unexposed parturients, and evaluated various respiratory outcomes
among those having a singleton late-preterm birth neonate. We controlled for potential
confounders including gestational age at delivery, diabetes, mode of delivery, and maternal race.
Results—Five thousand nine hundred twenty-four patients met the inclusion criteria; 550
received steroids, while 5,374 did not. In the univariable model, compared with unexposed
women, those who received antenatal corticosteroids appeared more likely to have neonates who
required ventilatory support (11.5% v. 8.6%, p=0.022), had respiratory distress syndrome (RDS)
(17.1% v. 12.2%, p=0.001), developed transient tachypnea of the newborn (12.9% v. 9.8%,
p=0.020), or required resuscitation in the delivery room (55.8% v. 49.7%, p=0.007). After
controlling for confounding factors, we found no significant differences among the groups
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regarding all of the above outcomes with an odds ratio for RDS of 0.78 (95% CI 0.60–1.02) and
ventilator support of 0.75 (95% CI 0.55–1.03).
Conclusion—Exposure to antenatal corticosteroids does not significantly affect respiratory
outcomes among those with a subsequent late-preterm birth.
INTRODUCTION
Approximately 75% of preterm births in the United States occur in the “late-preterm” period
between 340 and 366 weeks gestation(1). Since 1990, births in the late-preterm window
increased by approximately 25% (2). Until recently, the prevailing belief has been that
neonates born in the late-preterm period may have mild respiratory compromise requiring
brief periods of oxygen support, but that more severe and costly complications are
uncommon. This may have resulted in part by a statement made by the American Congress
of Obstetricians and Gynecologists saying that survival for newborns at 34 weeks of
gestation is within 1% of those born at 37 weeks or beyond(3). Although this remains true,
we are increasingly aware of the higher risk of short and long term morbidities that are more
frequent in this group when compared with neonates born at term (4–7).
The administration of antenatal corticosteroids (ACS) to women at risk for preterm delivery
has been shown to decrease the rate of respiratory distress syndrome (RDS) in neonates of
women who deliver between 24 and 34 weeks gestation (8–9). Although currently not
recommended in the late-preterm period, the lack of demonstrated benefit at advanced
gestations is thought to be due to the low incidence of RDS and the lack of adequately
powered studies to address these outcomes in this group. A recent Cochrane review found
less than 200 published cases of patients randomized to ACS or placebo between 35 and <37
weeks of gestation(9). Among these, there were only 6 cases of RDS. Given the evidence of
respiratory compromise in late-preterm neonates, we sought to estimate whether exposure to
ACS during pregnancy decreased the rate of respiratory morbidities if the pregnancy was
delivered during the late-preterm period.
METHODS
This was a secondary analysis from a multicenter observational study conducted by the
Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) Maternal-Fetal Medicine Units (MFMU) Network from 1999–2002 regarding
primary and repeat cesarean delivery. Full details of the methods and study design have been
previously reported(10). This secondary analysis was approved by the IRB at Columbia
University Medical Center.
Women with a singleton gestation resulting in late-preterm birth (LPTB) were identified.
Late preterm birth was defined as delivery occurring between 34 0/7 to 36 6/7 weeks
gestation. Gestational age was determined by best obstetric estimate in the parent study.
Women with multiple gestations were excluded from the parent study. Neonatal data were
collected up to discharge or 120 days post delivery, whichever came first, and data on ACS
exposure was abstracted from maternal charts. Women were considered to have ACS
exposure if they received corticosteroids for fetal lung maturity that cross the placenta in
significant amounts. Women receiving prednisone or other steroids not for lung maturity
were considered unexposed. Data on the specific corticosteroid received by each subject
were not obtained. Women were included if they never received steroids or if they
completed one course. Women who received multiple courses, partial dosing, or those for
whom information was incomplete were not included. Although it is not common practice to
administer ACS in the late-preterm period at the institutions that participated in the parent
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study, we could not ascertain the gestational age at steroid administration from our records.
Therefore, the time from ACS administration to delivery was not available in this dataset.
We compared women exposed to one course (2 or 4 doses) of ACS with unexposed
parturients, and evaluated neonatal respiratory outcomes such as RDS, transient tachypnea
of the newborn (TTN), ventilator use, and the need for resuscitation in the delivery room. In
multivariable analyses we controlled for potential confounders that might influence
respiratory outcomes. These include maternal diabetes (gestational and pregestational), race,
prenatal care insurance, mode of delivery, presence of labor, gestational age (GA) at
delivery, and congenital anomalies.
Our primary outcome was RDS. Secondary outcomes included TTN, ventilator use, and the
need for resuscitation in the delivery room. Additionally, a composite of respiratory
morbidities that included RDS, TTN, and ventilator support in the first 24 hours was
analyzed between groups. Categorical variables were compared using the chi-square test for
dichotomous variables, and the Wilcoxon rank-sum test was used for continuous variables.
Multivariable logistic regression was performed to control for the confounders listed above.
Odds ratios (OR) and 95% confidence intervals (CI) for various outcomes were determined.
Nominal two-sided probability values are reported with statistical significance defined as
P<0.05. No adjustments were made for multiple comparisons. Statistical analyses were
performed using SAS software (SAS Institute, Inc, Cary, NC).
RESULTS
70,442 women were enrolled in the Cesarean Registry. Of these, 5924 met eligibility criteria
for this secondary analysis; 550 received steroids and 5,374 did not (Figure 1). Maternal
characteristics of the study population by ACS exposure are described in Table 1. The
groups were similar in age and parity. Women who received ACS were more likely to be
Caucasian, have private insurance, and to be delivered by cesarean compared with women
who did not receive steroids. These women also delivered earlier, 34.9 (34.3–35.7) weeks
gestation (median [IQR]), than patients who did not receive steroids, 36.0 (35.5–36.6)
weeks, p<0.001.
Compared with unexposed women, those who were given ACS appeared more likely to
have neonates with RDS (17.1% v. 12.2%, p=0.001). ACS exposure was also related to
increased rates of TTN (12.9% v. 9.8%, p=0.020), increased need for ventilatory support
(11.5% v. 8.6%, p=0.022), higher rates of the adverse respiratory composite (29.9% v.
22.2%, p<0.001), and higher rates of resuscitation in the delivery room (55.8% v. 49.7%,
p=0.007). However, after controlling for the following confounders - maternal diabetes,
race, prenatal care insurance, mode of delivery, labor, GA at delivery and congenital
anomalies - women who received ACS had similar rates of all respiratory outcomes
compared with controls [Table 2].
DISCUSSION
We found that exposure to antenatal corticosteroids during pregnancy did not appear to
change the proportion of adverse respiratory outcomes in neonates born at 34 0/7 to 36 6/7
weeks when compared with offspring of unexposed parturients. Few prospective studies
have evaluated respiratory outcomes in late-preterm neonates exposed to steroids. In the first
randomized controlled trial of ACS to enhance fetal pulmonary maturation in 1972, Liggins
and Howie found that exposure to betamethasone decreased the rate of RDS from 25.8% in
controls to 9.0% in the treatment group, p=0.003(8). When they performed a subgroup
analysis evaluating neonates delivered between 32 to <37 weeks gestation, they found a
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lower rate of RDS from 6.9% in the control group to 4.7% in the treatment group; a similar
risk reduction to that seen with delivery at earlier gestations, but statistical significance was
not reached. Notably, there were only 4 cases of RDS in that cohort of 72 moderately
preterm neonates. The most recent Cochrane systematic review evaluating the rates of RDS
in fetuses exposed to steroids who delivered at 34 weeks gestation or beyond found a similar
trend but significance was again not reached in control versus treatment groups, 4.7% versus
3.1%, Risk Ratio 0.66, 95% CI 0.38–1.16, p=0.15(9). Of 1,261 included subjects, there were
only 49 cases of RDS. The risk ratio for RDS among 189 newborns delivered at 35–36
weeks gestation was similar (Risk Ratio 0.61, 95% CI 0.11–3.26). Like Liggins’ study and
this recent meta-analysis, our evaluation lacks the needed power to resolve this issue.
However, it is reassuring that our multivariable analyses revealed similar results to those
previously published.
Biologically, there is no good explanation supporting a cessation of benefit to ACS after 34
weeks gestation. Rather, it is more likely that a decrease in the disease burden makes
demonstration of this benefit more difficult. Late-preterm neonates are less likely to have
RDS than neonates born before 34 weeks; however, they are still at risk for respiratory
morbidities from other causes. As a pregnancy approaches term, delivery is more likely to
result in TTN than RDS. Rubaltelli et al, were one of the first groups to evaluate the
etiologies of acute respiratory distress in the late-preterm cohort(11). They found that the
rate of TTN at 34 to 36 weeks was higher than that of babies born beyond 36 weeks, 6.2%
versus 0.4%. Escobar and colleagues evaluated the need for respiratory support among late-
preterm neonates compared with those delivered between 38 and 40 weeks gestation(6).
They found that babies born at 34, 35, and 36 weeks were 19.8-, 9.0-, and 5.2-fold more
likely respectively to require assisted ventilation compared with the reference group born at
38 to 40 weeks. Other groups have also demonstrated higher respiratory morbidity in late-
preterm compared with term neonates(4, 7). These data validate the suggestion that late-
preterm neonates are at risk for serious respiratory morbidities other than RDS which impact
their early neonatal management. What is currently unknown is whether ACS administration
can decrease these other respiratory morbidities.
A limitation to our study is that we do not know the gestational age at which the steroids
were given, and thus the time interval between ACS administration and delivery. This is an
important confounder as the effects of ACS administration are believed to be of limited
duration. None of the participating clinical centers in the parent study routinely administer
ACS after 34 weeks gestation, so it is likely that the majority of exposed newborns had been
exposed to ACS remote from delivery; and it is unlikely that ACS were administered
beyond 34 weeks. Additionally, this secondary analysis evaluates the impact of ACS
administration on those delivering at 34–36 weeks rather than the impact of steroids
administered at 34–36 weeks on those delivering thereafter. Recently, a group of
investigators evaluated the role of ACS to decrease respiratory morbidities including, but not
limited to, RDS in a term population undergoing planned cesarean delivery(12). They
randomized women over 37 weeks gestation to betamethasone versus routine management
and evaluated rates of admission of their neonates to a special care unit for respiratory
distress. They found that the newborns of women who received steroids were less likely to
require admission to a special care unit compared with neonates of women who did not,
0.024 versus 0.051%, (Relative Risk (RR) 0.46, 95% CI 0.23–0.93). They also found a
lower rate of RDS in the treated group, 0.002% versus 0.011%, but statistical significance
was not reached,(RR 0.32, 95% CI 0.03– 1.32). Based on these findings, it is plausible that
ACS administration at 34–36 weeks to women at risk for late-preterm birth could also result
in improved pulmonary outcomes. Finally, this is a secondary analysis of a prior completed
trial and therefore, our sample size is fixed and limited.. Perhaps this difference would have
been detectable with a larger sample size.
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Our findings regarding the effect of ACS in the late-preterm period are consistent with prior
reports, but highlight that adequate power to make clinical recommendations based on these
studies is lacking. These studies support the need for well-designed trials of adequate size to
evaluate the impact of antenatal corticosteroid administration in the late-preterm period for
reduction of newborn respiratory complications.
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Maternal age at delivery 28.9 ± 6.5 28.7 ± 6.4 0.55
Gestational age at delivery (median [IQR]) 34.9 (34.3–35.7) 36.0 (35.5–36.6) <0.001
Nulliparous 121 (22.2) 1112 (20.8) 0.47
Cesarean delivery 470 (85.5) 4406 (82.0) 0.042
Diabetes 82 (14.9) 827 (15.4) 0.76
Labor 273 (49.6) 3076 (57.2) <0.001
Insurance for prenatal care Government 256 (49.4) 2891 (58.3) <0.001
Private 262 (50.6) 2068 (41.7)
Congenital anomalies 22 (4.0 ) 231 (4.3) 0.74
IQR interquartile range.
Data are n (%) or mean ± standard deviation.
Data on prenatal care insurance were missing for 32 (5.8%) women in the antenatal corticosteroids group and 415 (7.7%) of women in the no
antenatal corticosteroids group, or 447 (7.5%) overall.
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Table 2











Respiratory distress syndrome 94 (17.1) 652 (12.2) 1.49 (1.18–1.89) 0.78 (0.60–1.02)
Ventilatory support 63 (11.5) 459 (8.6) 1.38 (1.05–1.83) 0.75 (0.55–1.03)
Transient tachypnea of the newborn 71 (12.9) 525 (9.8) 1.37 (1.05–1.78) 1.10 (0.83–1.47)
Resuscitation in the delivery room 307 (55.8) 2672 (49.7) 1.28 (1.07–1.52) 0.89 (0.73–1.09)
Composite (RDS, TTN, ventilatory support) 164 (29.9) 1188 (22.2) 1.50 (1.23–1.82) 0.88 (0.71–1.10)
RDS, respiratory distress syndrome; TTN, transient tachypnea of the newborn.
*
Adjusted for maternal diabetes, race, prenatal care insurance, mode of delivery, labor, gestational age at delivery, and congenital anomalies.
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